This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Keryx Pharma

It's a reasonable argument to make, except, "If the earlier perifosine data are so good, why hasn't Keryx been bought out yet," asks Ratain.

Good question!

When Ratain and I were working on our JNCI paper, we recognized that one reason micro-cap cancer drug stocks had a perfectly dismal record with phase III trials is because the drugs being developed had already been vetted by both the market (i.e., investors) and larger, more successful cancer drug companies and found to have a low probability of success.

Cancer drugs are scarce and valuable commodities. Larger drug companies are way more likely to acquire, or at least partner with, a smaller drug company if that smaller company has a cancer drug in development with a strong shot at being successful.

Keryx has already stated publicly that it hopes to attract a buyer for the company. Yet, as Keryx nears the end of its colon cancer phase III study, the company is still independent -- no perifosine buyer, no partner either. [<b>Aeterna Zentaris</b> <span class=" TICKERFLAT">(<a href="/quote/AEZS.html">AEZS</a> - <a href="http://secure2.thestreet.com/cap/prm.do?OID=028198&amp;ticker=AEZS">Get Report</a><a class=" arrow" href="/quote/AEZS.html"><span class=" tickerChange" id="story_AEZS"></span></a>)</span>, which owns ex-U.S. rights to the drug, doesn't count.]

What's more likely to have happened already, says Ratain (and I agree with him) is that larger companies have already vetted the previous perifosine data and found it lacking. That makes Keryx look very much like the 21 micro-cap cancer drug companies included in the analysis done by Ratain and myself for JNCI. And that's not the group you want to be associated with.

Keryx and perifosine is an ideal, prospective test of whether stock market value can predict cancer drug trial outcomes. I'm looking forward to early next year when Keryx announces the perifosine results.

Some quick hits:

I mentioned on Twitter last week that Rodman & Renshaw was inviting investors to a "non-deal" road show for Cell Therapeutics (CTIC - Get Report) in New York City on Oct. 19.

To which Zacks analyst Jason Napodano (@JNapodano) replied, "There's no such thing as a "non-deal" show with R&R."

So true. Expect Cell Therapeutics to raise money again real soon.

Alan P. asks me to predict the outcome of the shareholder vote on the proposed merger between Amag Pharmaceuticals (AMAG - Get Report) and Allos Therapeutics (ALTH). The vote is scheduled for Oct. 21.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CTIC $1.58 0.00%
AEZS $0.09 0.00%
AMAG $64.99 0.00%
KERX $6.03 0.00%
SPPI $6.62 0.00%

Markets

Chart of I:DJI
DOW 16,351.38 +293.03 1.82%
S&P 500 1,948.86 +35.01 1.83%
NASDAQ 4,749.9790 +113.8740 2.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs